An external skin preparation comprises the following components (A) to (E), wherein the mass ratio of the component (A) to the component (B), (A)/(B), is from 0.3 to 2.0, wherein the content of the component (C) is from 0.1 to 1 mass %, and wherein the preparation has a pH at 25° C. of from 4.0 to 7.0: (A) one or more selected from the group consisting of aliphatic alcohols having from 14 to 20 carbon atoms; (B) two or more selected from the group consisting of polyhydric alcohol fatty acid ester-type nonionic surfactants; (C) one or more selected from the group consisting of N-acyl amino acids, N-acyl taurine, salts thereof, and phospholipids; (D) one or more selected from the group consisting of steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, and heparinoids; and (E) water.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

An article of manufacture according to the present invention comprises a composition including a glycosaminoglycan, a local anesthetic, and a buffer packaged in a syringe or vial constructed from either glass or a plastic selected from the group consisting of cyclic olefin polymer, cyclic olefin copolymer, or high density non-nucleated polypropylene. The composition has unexpectedly improved stability on storage. The composition can be formulated for treatment of a urinary tract disease or condition, such as interstitial cystitis, also known as bladder pain syndrome or hypersensitive bladder syndrome.

An article of manufacture according to the present invention comprises a composition including a glycosaminoglycan, a local anesthetic, and a buffer packaged in a syringe or vial constructed from either glass or a plastic selected from the group consisting of cyclic olefin polymer, cyclic olefin copolymer, or high density non-nucleated polypropylene. The composition has unexpectedly improved stability on storage. The composition can be formulated for treatment of a urinary tract disease or condition, such as interstitial cystitis, also known as bladder pain syndrome or hypersensitive bladder syndrome.

The invention provides a device comprising: at least one biocompatible polymer, and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.

The invention provides a device comprising: at least one biocompatible polymer, and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.